Technology evaluation: alicaforsen (Isis).
Isis is developing alicaforsen, an RNase H-dependent antisense inhibitor of intercellular adhesion molecule-1, for the potential treatment of ulcerative colitis. The therapy is currently undergoing phase II clinical trials.
Emory University School of Medicine, Department of Pathology and Laboratory Medicine, Atlanta, GA 30322, USA. agewirt@emory.edu
Andrew T
AT
Gewirtz
Shanthi V
SV
Sitaraman
D000818:Animals; D017322:Clinical Trials, Phase II as Topic; D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D020319:Oligodeoxyribonucleotides, Antisense / Q000009:adverse effects / Q000627:therapeutic use*; D054735:Phosphorothioate Oligonucleotides; D013873:Thionucleotides / Q000009:adverse effects / Q000627:therapeutic use*
D020319:Oligodeoxyribonucleotides, Antisense; D054735:Phosphorothioate Oligonucleotides; D013873:Thionucleotides; C089753:alicaforsen